受强制性开放获取政策约束的文章 - Peter Ellis了解详情
无法在其他位置公开访问的文章：7 篇
Assessment of referral and chemotherapy treatment patterns for elderly patients with non–small-cell lung cancer
DE Dawe, GR Pond, PM Ellis
Clinical lung cancer 17 (6), 563-572. e2, 2016
强制性开放获取政策： Canadian Institutes of Health Research, Ontario Institute for Cancer Research
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
RA Juergens, D Hao, PM Ellis, D Tu, M Mates, C Kollmannsberger, ...
Lung Cancer 143, 1-11, 2020
强制性开放获取政策： Canadian Cancer Society
The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada
J Doherty, DE Dawe, GR Pond, PM Ellis
Journal of Geriatric Oncology 10 (3), 449-458, 2019
强制性开放获取政策： Ontario Institute for Cancer Research
Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy
S Dhesy-Thind, V Kumar, A Snider-McNair, C Shortt, SD Mukherjee, ...
Clinical Chemistry 59 (1), 327-329, 2013
强制性开放获取政策： Ontario Institute for Cancer Research
Cardiac morbidity following chemoradiation in stage III non-small cell lung cancer patients: a population-based cohort study
EK Donovan, GR Pond, H Seow, PM Ellis, A Swaminath
Clinical Oncology 35 (2), e182-e188, 2023
强制性开放获取政策： Canadian Institutes of Health Research, Ontario Institute for Cancer Research
BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate …
R Sur, G Pond, C Falkson, M Pan, J Wright, A Bezjak, A Dagnault, E Yu, ...
International Journal of Radiation Oncology* Biology* Physics 116 (3), 601-610, 2023
强制性开放获取政策： Canadian Cancer Society
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable …
J Nehra, PA Bradbury, PM Ellis, J Laskin, C Kollmannsberger, D Hao, ...
Investigational New Drugs 38, 1442-1447, 2020
强制性开放获取政策： Canadian Cancer Society
可在其他位置公开访问的文章：13 篇
Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update
NH Hanna, AG Robinson, S Temin, S Baker Jr, JR Brahmer, PM Ellis, ...
Journal of Clinical Oncology 39 (9), 1040-1091, 2021
强制性开放获取政策： Lung Cancer Research Foundation, USA
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised, phase 3 trial
PM Ellis, FA Shepherd, M Millward, F Perrone, L Seymour, G Liu, S Sun, ...
The Lancet Oncology 15 (12), 1379-1388, 2014
强制性开放获取政策： National Health and Medical Research Council, Australia, Canadian Cancer Society
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials …
SA Laurie, BJ Solomon, L Seymour, PM Ellis, GD Goss, FA Shepherd, ...
European journal of cancer 50 (4), 706-712, 2014
强制性开放获取政策： Canadian Cancer Society
Metformin in combination with chemoradiotherapy in locally advanced non–small cell lung cancer: The OCOG-ALMERA randomized clinical trial
T Tsakiridis, GR Pond, J Wright, PM Ellis, N Ahmed, B Abdulkarim, W Roa, ...
JAMA oncology 7 (9), 1333-1341, 2021
强制性开放获取政策： Canadian Institutes of Health Research
Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial
DP Leong, T Cosman, MM Alhussein, N Kumar Tyagi, S Karampatos, ...
Cardio Oncology 1 (1), 1-10, 2019
强制性开放获取政策： Heart and Stroke Foundation of Canada
Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
MAM Farooqi, N Malhotra, SD Mukherjee, S Sanger, SK Dhesy-Thind, ...
PloS one 13 (12), e0209486, 2018
强制性开放获取政策： Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada
Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with Non–Small cell lung cancer treated with epidermal growth …
A Zer, K Ding, SM Lee, GD Goss, L Seymour, PM Ellis, A Hackshaw, ...
Journal of thoracic oncology 11 (3), 312-323, 2016
强制性开放获取政策： US National Institutes of Health, Canadian Cancer Society, Cancer Research UK
NCIC CTG IND. 190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer
PM Ellis, FA Shepherd, SA Laurie, GD Goss, M Olivo, J Powers, ...
Journal of Thoracic Oncology 9 (3), 410-413, 2014
强制性开放获取政策： Canadian Cancer Society
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
NB Leighl, SA Laurie, XE Chen, P Ellis, FA Shepherd, JJ Knox, G Goss, ...
Journal of Thoracic Oncology 4 (9), 1163-1169, 2009
强制性开放获取政策： US National Institutes of Health
Value assessment of oncology drugs using a weighted criterion‐based approach
DA Ezeife, F Dionne, AF Fares, ELR Cusano, R Fazelzad, W Ng, ...
Cancer 126 (7), 1530-1540, 2020
强制性开放获取政策： Canadian Institutes of Health Research
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
OD Biziotis, EE Tsakiridis, A Ali, E Ahmadi, J Wu, S Wang, B Mekhaeil, ...
Molecular Oncology 17 (11), 2235-2256, 2023
强制性开放获取政策： Canadian Institutes of Health Research, Natural Sciences and Engineering …
OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗
T Tsakiridis, P Ellis, JC Cutz, G Pond, M Wierzbicki, P Kavsak, J Wright
Journal of Thoracic Oncology 11 (2), S50-S51, 2016
强制性开放获取政策： Canadian Institutes of Health Research
Detection of macrotroponin in patients receiving treatment for breast cancer
PA Kavsak, B Hoard, K Mackett, SD Mukherjee, L Bordeleau, PM Ellis, ...
CJC open 5 (8), 658, 2023
强制性开放获取政策： Canadian Institutes of Health Research
出版信息和资助信息由计算机程序自动确定